Faderl S, Talpaz M, Estrov Z, O’Brien S, Kurzrock R, Kantarjian HM. The biology of chronic myeloid leukemia. N Engl J Med. 1999;341(3):164–72. https://doi.org/10.1056/NEJM199907153410306.

Article  CAS  PubMed  Google Scholar 

Cortes J, Pavlovsky C, Saußele S. Chronic myeloid leukaemia. Lancet. 2021;398(10314):1914–26. https://doi.org/10.1016/S0140-6736(21)01204-6.

Article  CAS  PubMed  Google Scholar 

Hehlmann R. Innovation in hematology. Perspectives: CML 2016. Haematologica. 2016;101(6):657–9. https://doi.org/10.3324/haematol.2016.142877.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, et al. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med. 2017;376(10):917–27. https://doi.org/10.1056/NEJMoa1609324.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34(4):966–84. https://doi.org/10.1038/s41375-020-0776-2.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Deininger MW, Shah NP, Altman JK, Berman E, Bhatia R, Bhatnagar B, et al. Chronic myeloid leukemia, version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2020;18(10):1385–415. https://doi.org/10.6004/jnccn.2020.0047.

Article  CAS  PubMed  Google Scholar 

Kizaki M, Takahashi N, Iriyama N, Okamoto S, Ono T, Usui N, et al. Efficacy and safety of tyrosine kinase inhibitors for newly diagnosed chronic-phase chronic myeloid leukemia over a 5-year period: results from the Japanese registry obtained by the New TARGET system. Int J Hematol. 2019;109(4):426–39. https://doi.org/10.1007/s12185-019-02613-1.

Article  CAS  PubMed  Google Scholar 

Cortes JE, Saglio G, Kantarjian HM, Baccarani M, Mayer J, Boqué C, et al. Final 5-year study results of DASISION: the Dasatinib Versus Imatinib Study in treatment-naïve chronic myeloid leukemia patients trial. J Clin Oncol. 2016;34(20):2333–40. https://doi.org/10.1200/JCO.2015.64.8899.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kantarjian HM, Hughes TP, Larson RA, Kim DW, Issaragrisil S, le Coutre P, et al. Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis. Leukemia. 2021;35(2):440–53. https://doi.org/10.1038/s41375-020-01111-2.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Brümmendorf TH, Cortes JE, Milojkovic D, Gambacorti-Passerini C, Clark RE, le Coutre P, et al. Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial. Leukemia. 2022;36(7):1825–33. https://doi.org/10.1038/s41375-022-01589-y.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122(6):872–84. https://doi.org/10.1182/blood-2013-05-501569.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transpl. 2013;48(3):452–8. https://doi.org/10.1038/bmt.2012.244.

Article  CAS  Google Scholar 

Tauchi T, Kizaki M, Okamoto S, Tanaka H, Tanimoto M, Inokuchi K, et al. Seven-year follow-up of patients receiving imatinib for the treatment of newly diagnosed chronic myelogenous leukemia by the TARGET system. Leuk Res. 2011;35(5):585–90. https://doi.org/10.1016/j.leukres.2010.10.027.

Article  CAS  PubMed  Google Scholar 

Ohnishi K, Nakaseko C, Takeuchi J, Fujisawa S, Nagai T, Yamazaki H, et al. Long-term outcome following imatinib therapy for chronic myelogenous leukemia, with assessment of dosage and blood levels: the JALSG CML202 study. Cancer Sci. 2012;103(6):1071–8. https://doi.org/10.1111/j.1349-7006.2012.02253.x.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nakamae H, Yamamoto M, Sakaida E, Kanda Y, Ohmine K, Ono T, et al. Nilotinib vs. imatinib in Japanese patients with newly diagnosed chronic myeloid leukemia in chronic phase: 10-year follow-up of the Japanese subgroup of the randomized ENESTnd trial. Int J Hematol. 2022;115(1):33–42. https://doi.org/10.1007/s12185-021-03216-5.

Article  CAS  PubMed  Google Scholar 

Nakamae H, Fujisawa S, Ogura M, Uchida T, Onishi Y, Taniwaki M, et al. Dasatinib versus imatinib in Japanese patients with newly diagnosed chronic phase chronic myeloid leukemia: a subanalysis of the DASISION 5-year final report. Int J Hematol. 2017;105(6):792–804. https://doi.org/10.1007/s12185-017-2208-2.

Article  CAS  PubMed  Google Scholar 

Imagawa J, Tanaka H, Okada M, Nakamae H, Hino M, Murai K, et al. Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial. Lancet Haematol. 2015;2(12):e528-35. https://doi.org/10.1016/S2352-3026(15)00196-9.

Article  PubMed  Google Scholar 

Takahashi N, Tauchi T, Kitamura K, Miyamura K, Saburi Y, Hatta Y, et al. Deeper molecular response is a predictive factor for treatment-free remission after imatinib discontinuation in patients with chronic phase chronic myeloid leukemia: the JALSG-STIM213 study. Int J Hematol. 2018;107(2):185–93. https://doi.org/10.1007/s12185-017-2334-x.

Article  CAS  PubMed  Google Scholar 

Takahashi N, Nishiwaki K, Nakaseko C, Aotsuka N, Sano K, Ohwada C, et al. Treatment-free remission after two-year consolidation therapy with nilotinib in patients with chronic myeloid leukemia: STAT2 trial in Japan. Haematologica. 2018;103(11):1835–42. https://doi.org/10.3324/haematol.2018.194894.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kumagai T, Nakaseko C, Nishiwaki K, Yoshida C, Ohashi K, Takezako N, et al. Dasatinib cessation after deep molecular response exceeding 2 years and natural killer cell transition during dasatinib consolidation. Cancer Sci. 2018;109(1):182–92. https://doi.org/10.1111/cas.13430.

Article  CAS  PubMed  Google Scholar 

Yamaguchi H, Takezako N, Ohashi K, Oba K, Kumagai T, Kozai Y, et al. Treatment-free remission after first-line dasatinib treatment in patients with chronic myeloid leukemia in the chronic phase: the D-NewS Study of the Kanto CML Study Group. Int J Hematol. 2020;111(3):401–8. https://doi.org/10.1007/s12185-019-02801-z.

Article  CAS  PubMed  Google Scholar 

Kimura S, Imagawa J, Murai K, Hino M, Kitawaki T, Okada M, et al. Treatment-free remission after first-line dasatinib discontinuation in patients with chronic myeloid leukaemia (first-line DADI trial): a single-arm, multicentre, phase 2 trial. Lancet Haematol. 2020;7(3):e218-25. https://doi.org/10.1016/S2352-3026(19)30235-2.

Article  PubMed  Google Scholar 

Narlı Özdemir Z, Kılıçaslan NA, Yılmaz M, Eşkazan AE. Guidelines for the treatment of chronic myeloid leukemia from the NCCN and ELN: differences and similarities. Int J Hematol. 2023;117(1):3–15. https://doi.org/10.1007/s12185-022-03446-1.

Article  PubMed  Google Scholar 

Pfirrmann M, Baccarani M, Saussele S, Guilhot J, Cervantes F, Ossenkoppele G, et al. Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia. Leukemia. 2016;30(1):48–56. https://doi.org/10.1038/leu.2015.261.

Article  CAS  PubMed  Google Scholar 

Molica M, Canichella M, Alunni Fegatelli D, Colafigli G, Massaro F, Latagliata R, et al. The Eutos long-term survival score accurately predicts the risk of death in chronic myeloid leukaemia patients treated outside of clinical trials. Am J Hematol. 2017;92(12):E661-4. https://doi.org/10.1002/ajh.24913.

Article  PubMed  Google Scholar 

Geelen IGP, Sandin F, Thielen N, Janssen JJWM, Hoogendoorn M, Visser O, et al. Validation of the EUTOS long-term survival score in a recent independent cohort of “real world” CML patients. Leukemia. 2018;32(10):2299–303. https://doi.org/10.1038/s41375-018-0136-7.

Article  PubMed  Google Scholar 

Pfirrmann M, Clark RE, Prejzner W, Lauseker M, Baccarani M, Saussele S, et al. The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia. Leukemia. 2020;34(8):2138–49. https://doi.org/10.1038/s41375-020-0931-9.

Article  PubMed  PubMed Central  Google Scholar 

Specchia G, Pregno P, Breccia M, Castagnetti F, Monagheddu C, Bonifacio M, et al. Prognostic factors for overall survival in chronic myeloid leukemia patients: a multicentric cohort study by the Italian CML GIMEMA Network. Front Oncol. 2021;11: 739171. https://doi.org/10.3389/fonc.2021.739171.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Szczepanek E, Chukwu O, Kamińska M, Wysogląd H, Cenda A, Zawada M, et al. Long-term outcomes of patients with chronic myeloid leukemia who commenced treatment with imatinib: a 20-year single-centre experience. Leuk Lymphoma. 2022;63(9):2213–23. https://doi.org/10.1080/10428194.2022.2068000.

Article  CAS  PubMed  Google Scholar 

Yang X, Bai Y, Shi M, Zhang W, Niu J, Wu C, et al. Validation of the EUTOS long-term survival score in Chinese chronic myeloid leukemia patients treated with imatinib: a Multicenter Real-World Study. Cancer Manag Res. 2020;12:1293–301. https://doi.org/10.2147/CMAR.S237467.

Article  CAS  PubMed  PubMed Central